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Invasive Salmonella disease in Africa is a major public health concern. With evidence of the transcontinental
spread of the Salmonella Typhi H58 haplotype, improved estimates of the burden of infection and understand-
ing of the complex interplay of factors affecting disease transmission are needed to assist with efforts aimed at
disease control. In addition to Salmonella Typhi, invasive nontyphoidal Salmonella are increasingly recognized
as an important cause of febrile illness and mortality in sub-Saharan Africa. Human experimental oral chal-
lenge studies with Salmonella can be used as a model to offer unique insights into host–pathogen interactions
as well as a platform to efﬁciently test new diagnostic and vaccine candidates. In this article, we review the back-
ground and use of human challenge studies to date and discuss how ﬁndings from these studies may lead to
progress in the control of invasive Salmonella disease in Africa.
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There is a pressing need to systematically address the
problem of invasive Salmonella disease in Africa [1,
2]; however, current epidemiological evidence suggests
a complex and dynamic situation across the continent.
The few accurate prevalence data for Salmonella enter-
ica subspecies enterica serovars Typhi and Paratyphi,
responsible for causing enteric fever, demonstrate a pre-
ponderance of Salmonella Typhi with marked geo-
graphic variation and urban localization [3]. In some
urban slums areas, for example, rates seen are compara-
ble to those in Southeast Asia [4]. Recent events include
the rapid dominance of an emerging Salmonella Typhi
haplotype, termed H58, associated with multidrug re-
sistance and occasional reduced ﬂuoroquinolone sus-
ceptibility [4–7]. Recent phylogeographical analysis
has demonstrated an increasing incidence of Salmonella
Typhi H58 across Africa over the past 30 years, follow-
ing multiple transmission events from Asia. The intro-
duction of H58 appears to be associated with clonal
replacement of resident non-H58 antibiotic-susceptible
strains, resulting in transformation of the Salmonella
Typhi epidemiology across Africa and the occurrence
of multidrug-resistant outbreaks in regions where the
disease was previously underappreciated [7].
In Africa, the problem of invasive Salmonella disease
is exacerbated by high rates of invasive nontyphoidal
Salmonella (iNTS) infection, caused by serovars of
Salmonella enterica other than Typhi or Paratyphi. In
this setting, the estimated annual incidence of iNTS dis-
ease approaches 227 per 100 000 population [8], and
recognized susceptibility factors include younger age
(6 months to 3 years), malnutrition, and comorbid ma-
laria or human immunodeﬁciency virus infection [2].
NTS strains most commonly isolated from bacteremic,
febrile patients vary by location but frequently include
Salmonella Typhimurium and Salmonella Enteritidis
[9]. Sequencing of isolates from across sub-Saharan
Africa has identiﬁed Salmonella Typhimurium multilo-
cus sequence type 313 (ST313) as the major cause of in-
vasive disease in the region. Further whole-genome
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sequencing has identiﬁed interesting converging evolutionary
changes by the ST313 strain toward a genotype resembling
the classic enteric fever-causing Salmonella serovars. These
changes are characterized by degradation of the genomic reper-
toire by multiple gene deletions and pseudogene formation.
This suggests that ST313 may have undergone recent host adap-
tation to a human niche, as has Salmonella Typhi sometime in
the last few thousand years [10, 11].
Further understanding of the host–pathogen dynamics that
occur during invasive Salmonella disease is required to recognize
factors affecting disease transmission and human immune re-
sponses to infection. Recently, a program of typhoid and paraty-
phoid human challenge studies has been undertaken by the
Oxford Vaccine Group at the University of Oxford based on pre-
vious typhoid challenge work performed by the University of
Maryland School of Medicine. These studies aim to address sev-
eral critical knowledge gaps, thereby informing disease transmis-
sion models and accelerating the development of public health
improvement strategies. In this article, we review the background
and use of human challenge studies to date and discuss how ﬁnd-
ings from these studies can offer insights to assist with the control
of typhoidal Salmonella disease. We also discuss the feasibility
and complexities of developing a human challenge study of
NTS disease, and how such a model could help to inform public
health strategies to control iNTS disease in Africa.
DEVELOPMENT OF HUMAN TYPHOID
CHALLENGE STUDIES
A systematic program of Salmonella Typhi challenge studies
was undertaken in Maryland between 1952 and 1974. Through
meticulous collection of clinical and microbiological data from
almost 2000 participants, many new advances were made in the
understanding of typhoid infection pathogenesis and human
responses to infection [12, 13]. These studies also demonstrated
the safety and utility of human challenge models in vaccine
evaluation, as exempliﬁed by assessment of oral Ty21a vaccina-
tion [14, 15].
In 2011, the Oxford Vaccine Group at the University of Ox-
ford reestablished a Salmonella Typhi human challenge model
with the speciﬁc aim of creating a platform to assess novel vac-
cine candidates [16]. The model developed uses an outpatient,
ambulatory design selecting healthy adults aged 18–60 years
who undergo a rigorous screening process before enrollment
[16].Although the ethical and design considerations are beyond
the scope of this review, they have been summarized elsewhere
[17–19]. To date, >160 participants have been safely challenged
in the Oxford studies.
Oral challenge is performed using a deﬁned dose of Salmo-
nella Typhi suspended in sodium bicarbonate solution. Follow-
ing challenge, participants are reviewed daily for 14 days, with
regular assessments made of clinical and symptomatic features,
routine biochemical/hematological measurements, and daily
blood and stool cultures. A diagnosis of enteric fever requires
participants to meet predeﬁned criteria of fever ≥38°C lasting
≥12 hours and/or Salmonella Typhi bacteremia, after which a
2-week course of oral antibiotics is commenced. Participants
who reach the 14th day of challenge without meeting diagnostic
criteria are also treated with antibiotics [16]. The highly inten-
sive and controlled nature of these types of studies enables the
longitudinal tracking of a disease process from a deﬁned point
of exposure through to infection, diagnosis, and treatment, al-
lowing observations and measurements to be made that would
be difﬁcult to obtain in natural infection.
Infectious Dose
The infectious dose of Salmonella bacteria required to induce clin-
ical illness is an important factor to understand when assessing
disease transmission and control methods [20, 21]. In the initial
typhoid challenge study performed at Oxford, a predetermined
dose escalation strategy was followed, starting with a dose of
103 colony-forming units (CFU), increasing in log-fold incre-
ments, until an attack rate of 60%–75% was achieved [16]. An at-
tack rate of 55% was observed with a challenge dose of 103 CFU,
rising to 65% at 104 CFU [16]. Although the same Salmonella
Typhi Quailes strain was used in both the Oxford and Maryland
studies, the coadministration of sodium bicarbonate buffer imme-
diately prior to challenge in the Oxford study resulted in a 4-log10
lowerdose of SalmonellaTyphi required toproduce an attack rateof
65% [22].Whereas lower levels of pathogen exposure are thought
to more accurately reﬂect natural infection with Salmonella Typhi,
differences in attack rate observed between the Oxford and Mary-
land studies may in part be attributable to methodical factors in-
cluding the deﬁnition of enteric fever used [16, 23], method of
challenge agent preparation [22], and use of bicarbonate buffer
[16], as well as preexisting immunity of study volunteers.
Blood Culture Surveillance
In the Oxford study, daily blood cultures were taken from all par-
ticipants from 12 hours after challenge until day 14 or 96 hours
postdiagnosis. A minority of participants (3/24 [12.5%]) were di-
agnosed with enteric fever based upon clinical criteria alone
(fever ≥38°C lasting ≥12 hours) without evidence of bacteremia.
This ﬁnding highlights the relatively low sensitivity of automated
blood culture even with repeated sampling in a high-income set-
ting, supporting the view that reliance on blood culture alone
may underestimate the true disease burden in African settings
where multiple alternative causes for fever exist.
Conversely, 4 of 24 diagnosed participants (16.6%) in our
model had detectable Salmonella Typhi bacteremia without
clinical signs of enteric fever. Two of these 4 participants had
a signiﬁcant increase in anti-lipopolysaccharide (LPS) antibody
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from a low baseline titer, suggesting that the humoral immune
system was exposed to the bacteria at some point after challenge
(unpublished observations). Subclinical or asymptomatic infec-
tion has long been suspected to occur following exposure to Sal-
monella Typhi and may play an important role in onward
disease transmission. Human challenge studies permit the de-
tailed assessment of this subset of people, who are difﬁcult to
evaluate in ﬁeld settings, and these ﬁndings could in turn
have important implications for transmission modeling.
Stool Shedding
Knowledge of the pattern and extent of stool shedding, both
during acute infection and chronic carriage, was found to be
an important factor when modeling transmission dynamics
for Salmonella Typhi in Southeast Asia [24]. Prolonged stool
shedding likely increases transmission, particularly in regions
with poor sanitation [25]. Collection of daily stool samples dur-
ing the acute challenge phase and clearance stools after comple-
tion of antibiotics allows the opportunity to follow bacterial
shedding from time of bacterial ingestion to disease convales-
cence and bacterial clearance.
Data from the original Maryland challenge studies reveal a
complex picture of stool shedding during the early phase of
infection [26]. A proportion of participants who remained
asymptomatic were noted to excrete Salmonella Typhi in their
stools for several weeks. The frequency of excretion peaked at 2
weeks after challenge in both those who did and those who did
not develop typhoid disease, with stool cultures often remaining
positive for 3 weeks, after which the frequency of positive stool
cultures declined, such that all participants had negative stool
cultures by 6 weeks after challenge.
Whereas data on shedding during acute infection can be close-
ly monitored, the Oxford typhoid challenge model offers limited
scope to investigate shedding during chronic carriage as the latter
is prevented by effective antibiotic therapy. Samples are collected
a minimum of 2 weeks after completion of antibiotics to assess
for chronic carriage and long-term shedding. In addition to
this, participants with a history of gallbladder disease or ultraso-
nographic evidence of gallstones are excluded prior to study
enrollment. To date, there has been no evidence of long-term
Salmonella Typhi shedding in any challenged participant.
Diagnostics
Human challengemodels provide a controlled environment to de-
velop and test the sensitivity of new diagnostics assays. For exam-
ple, use of a novel culture polymerase chain reaction (PCR) assay
targeting the ﬂiC-d gene of Salmonella Typhi has resulted in the
detection of asymptomatic primary Salmonella Typhi DNAemia
from as little as 12 hours after challenge. Culture PCR was positive
within 5 days of challenge in 10 of 40 participants, all of whom
had negative routine blood culture during this period; 7 of 10
subsequently developed typhoid infection [27,28].Published diag-
nostic methods including antibody-in-lymphocyte supernatant
[29] and Salmonella Typhi–speciﬁc anti-LPS salivary immuno-
globulin A responses [30,31] have been assessed using the typhoid
challenge model and have produced variable results (unpublished
data). These differences in immunological responses may be due
in part to the short duration of illness and rapid commencement
of antibiotic treatment required in the challenge model.
Natural infection with Salmonella Typhi is associated with
antibody responses to a broad range of antigens including
outer membrane (eg, OmpC or OmpS) or secreted proteins
(eg, HlyE, CdtB) [32, 33]. Human challenge studies can aid in
the identiﬁcation of novel antigens for serological surveillance.
The use of high-throughput antigen microarrays may lead to
the identiﬁcation of serodiagnostic and seroprotective antigens,
which could be used to develop new rapid diagnostic assays or
novel vaccines [34]. Long-term follow-up of participants from
challenge studies offers the opportunity to assess for the persis-
tence of antibody after infection, which may be difﬁcult to
achieve in ﬁeld settings and knowledge of which will be key
for serosurveillance and serodiagnosis studies.
Assessing Vaccine Efﬁcacy
Vaccines, together with other public health interventions, will
play an important role in reducing the burden of disease caused
by human-restricted typhoidal Salmonella. Currently licensed
typhoid vaccines, parenteral Vi polysaccharide and oral live at-
tenuated Ty21a, have several limitations including moderate
vaccine efﬁcacy and contraindication for use in young children.
Human challenge studies provide the opportunity to assess
novel vaccine candidates in relation to vaccine efﬁcacy and im-
munogenicity prior to assessment in costly ﬁeld trials.
Proof-of-principle of this approach was provided by the Mary-
land studies where the attenuated strain Ty21a was shown to pro-
tect volunteers challenged with Salmonella Typhi [14].Our group
has also utilized the model to test novel vaccine candidates. Re-
cently we have investigated the protective efﬁcacy of M01ZH09, a
novel, single-dose, oral live attenuated vaccine [35], and Ty21a
compared to placebo using the challenge model (ClinicalTrials.
gov identiﬁer NCT01405521), providing novel data on the poten-
tial for this vaccine to protect against typhoid infection and data
relating to correlates of protection. The protective efﬁcacy of a
new Vi tetanus toxoid conjugate vaccine, Typbar-TCV (Bharat
Biotech International Ltd), will also be assessed using the typhoid
challenge model (ClinicalTrials.gov identiﬁer NCT02324751).
CONDUCTING HUMAN CHALLENGE STUDIES
IN ENDEMIC REGIONS
Findings from challenge studies in a highly selected group of
individuals in the United Kingdom may not directly correlate
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with those found in endemic regions. The response to enteric
pathogens or oral vaccines, for example, may differ in an Afri-
can setting due to preexisting natural immunity, genetic differ-
ences, or comorbid conditions [19, 36]. Malaria challenge
studies have been conducted in African sites for several years
in an attempt to account for some of these variables following
malaria challenge [37]. Furthermore, there is precedent for un-
dertaking human challenge studies with enteric pathogens in
resource-limited settings [38, 39]. Although undertaking a ty-
phoid (or NTS) challenge study in Africa would require careful
study design, detailed discussions between key stakeholders, and
signiﬁcant ﬁnancial investment, such studies may offer a means
to study disease in the population of interest. This would allow
further investigation into the impact variables such as previous
Salmonella exposure, dietary factors, intestinal microbiota, and
the genetic proﬁle of the host population, have on disease path-
ogenesis and host immune responses [40].
DEVELOPING AN NTS HUMAN CHALLENGE
MODEL
Given the increasing role of NTS strains in causing invasive Sal-
monella disease in Africa, in addition to the scientiﬁc and trans-
lational beneﬁts provided by established human enteric fever
challenge models, increasing attention has been given to the fea-
sibility of developing an NTS human challenge model [18]. A
controlled setting to study host–pathogen interactions, bacterial
dynamics, and assess NTS vaccine candidates would offer a
novel approach and a rapid way to advance our understanding
of NTS disease. Important considerations in the development of
an NTS human challenge model would include identiﬁcation
of an appropriate starting dose of challenge agent, development
of a suitable dose escalation strategy, and determining the need
for bicarbonate pretreatment to neutralize stomach acid prior to
challenge [41], in addition to the issues discussed below.
Strain Selection and Manufacture
Strain choice is integral to the design of a human challenge study.
Ingestion of the challenge strain needs to result in the required
disease endpoint, which is generally observable, reproducible
clinical infection. The early Maryland studies, for example, failed
to induce enteric fever after challenge with a variety of deposited
Ty2 strains [42], but successfully reproduced features of bactere-
mia and clinical symptomatology following challenge with the
Quailes strain of Salmonella Typhi—a Vi-expressing strain isolat-
ed from a then-recently diagnosed chronic carrier (Mrs Quailes)
[22, 43]. Challenge strains should also express the required viru-
lence characteristics and share features consistent with other cir-
culating strains, which will allow study ﬁndings to be applied to
contemporary ﬁeld settings. Undertaking a challenge study with
an H58 isolate of Salmonella Typhi, for example, would offer an
opportunity to understand host–pathogen interactions using a
strain of contemporary signiﬁcance. Based upon current knowl-
edge of NTS serovars and strains, Salmonella Typhimurium
ST313 would be an appropriate choice to develop as a challenge
agent, as it accounts for much of the iNTS disease seen in sub-
Saharan Africa and, similar to Salmonella Typhi, appears to
display features of human adaptation. In a similar fashion to
the development of the Salmonella Paratyphi challenge strain
(NVGH308), an isolate obtained from the blood culture of a clin-
ical case of paratyphoid infection in Kathmandu, Nepal
(NCT02100397), an ST313 isolate from the ﬁeld could, in theory,
also be isolated and manufactured to Good Manufacturing Prac-
tice standards for use in challenge studies. A series of quality con-
trol tests are performed before the strain can be used in human
challenge studies including antimicrobial susceptibility and
stability testing. In some settings, the substantial cost of strain
manufacture may represent a major barrier to the development
of an NTS challenge strain and, as such, signiﬁcant ﬁnancial in-
vestment and collaboration by funders and/or industrial partners
would be required.
Endpoint Deﬁnition
In enteric fever challenge studies, fever and/or bacteremia have
been used as objective measurable endpoints of infection. De-
ﬁning an endpoint after NTS challenge that is both safe and
clinically meaningful is particularly difﬁcult. Fever or bactere-
mia would represent the most clinically relevant features of
iNTS disease; however, it is uncertain if healthy, immunocom-
petent volunteers would develop inﬂammatory gastroenteritis
or invasive disease after challenge. Even in the African setting,
invasive disease is uncommon in healthy adults. Development
of bacteremia may be associated with a high risk of complica-
tions such as endovascular infection, meningitis, or septic
shock. Alternative endpoints could include diarrhea, isolation
of challenge agent from stool, or a predetermined duration of
stool shedding. Such endpoints have been used in other enteric
challenge studies and would be associated with less risk to study
participants. Although such a model would not address poten-
tially important factors related to invasive disease, such as sys-
temic host–pathogen interactions, it would assist with the study
of mucosal immunity, stool shedding, and the effect NTS vac-
cine candidates have on preventing gastroenteritis and bacterial
shedding, and as such, may have implications on preventing
NTS transmission in the ﬁeld.
Safety
The overall mortality rate of iNTS disease is estimated at 20% in
the African setting [8] and may be much higher in particular at-
risk groups [44]. The mortality rate of iNTS in high-income
countries, whereas lower than that seen in African settings, may
be as high as 5% [45]. The potential for serious complications
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including septic shock, endovascular infection, or meningitis
would be a potential concern if using systemic infection as an
endpoint [46], and consideration should be given to screen par-
ticipants for potential predisposing conditions, such as aneurys-
mal arterial disease or valvular heart disease. An inpatient NTS
challenge model could reduce the risk to participants by allow-
ing close clinical monitoring, cautious dose escalation, and
prompt antibiotic treatment as well as minimizing the risk of
transmission to close household contacts [47]. However, an in-
patient model would require dedicated facilities and staff, with
substantial attendant costs. Detailed discussion and agreement
between a range of key stakeholders, including the study team,
sponsors, public health services, regulatory agencies, and ethics
committees, would be required to minimize risk when design-
ing an NTS challenge model [17, 18].
CONCLUSIONS
Despite growing evidence demonstrating the signiﬁcant morbid-
ity and mortality caused by invasive Salmonella disease in Africa,
many factors relating to disease transmission remain unknown.
Human challenge studies can shed light on several of these un-
known areas including strain infectivity, duration of stool shed-
ding, and detection of early and late disease markers. Use of
typhoid challenge models also provides a platform to evaluate
novel vaccine candidates, which could play a key role in future dis-
ease control efforts given increasing rates of antimicrobial resis-
tance among Salmonella Typhi isolates from Africa. We have
shown that Salmonella Typhi human challenge models can be
performed safely and offer a unique means of studying disease
from the point of infection through to diagnosis, treatment, and
convalescence. An NTS human challenge model could offer sim-
ilar advantages of obtaining valuable human-speciﬁc data for a
currently neglected and serious disease, but several knowledge
gaps would have to be ﬁlled before such a model could be serious-
ly contemplated. While a number of well-described risk factors
for iNTS have been identiﬁed, invasive disease is a relatively infre-
quent occurrence in the African setting following exposure to
NTS serovars in the gastrointestinal tract. Human challenge stud-
ies could allow further exploration of the host and pathogen
factors associated with the iNTS phenotype; however, the unpre-
dictable response to a controlled challenge in healthy volunteers is
a potential hurdle. The low attack rate in the general population
may preclude the successful development of a model, even at high
challenge dose. On the other hand, there is a real potential for se-
rious complications with iNTS. Careful consideration of ways to
mitigate the risk to study participants may preclude development
of a human challenge model in the short term, but it is hoped that
insights from enteric fever challenge studies can beneﬁt ongoing
disease surveillance and contribute to the collaborative effort to
control invasive Salmonella disease across Africa.
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